A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: KarXT, Placebo.
- Кому может быть актуально
- Состояния в реестре: Bipolar Disorder Type I With Mania or Mania With Mixed Features. Базовые параметры: 18 лет — 65 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США, Китай, Хорватия, Индия, Израиль +6
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Обзор
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
Вмешательства
- Препарат KarXT
Specified dose on specified days - Другое Placebo
Specified dose on specified days
Первичные конечные точки
- Change from baseline in Young Mania Rating Scale (YMRS) score [Срок оценки: At week 3]
Вторичные конечные точки (3)
- Change from baseline in Clinical Global Impressions-Bipolar (CGI-BP) [Срок оценки: At week 3]
- Occurrence of response based on ≥ 50% decrease from baseline in YMRS score or total score [Срок оценки: At week 3]
- Occurrence of response based on change from baseline ≥ 1 in CGI-BP [Срок оценки: At week 3]
Критерии участия
Критерии включения
- Participants must have a primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation.
- Participants must be experiencing an acute episode or relapse of mania or mania with mixed features (≤ 3 weeks).
- Participants must require hospitalization for the acute exacerbation or relapse of mania.
- Participants must have all psychotropic medications washed out in no more than 14 days prior to the first dose of the study drug.
- Participants must have a Young Mania Rating Scale (YMRS) score of ≥ 20 at Screening and at Baseline.
- Participants must have a Clinical Global Impressions-Bipolar (CGI-BP) ≥ 4 at Screening and at Baseline.
Критерии исключения
- Participants must not have any primary Diagnostic and Statistical Manual of Mental Disorders (5th Edition, Text Revision) (DSM-5-TR) disorder, other than BP-I with mania or mania with mixed features within 12 months before screening, including BP-I with depression (for previous 3 months only), BP-II disorder, borderline personality disorder, major depressive disorder, and primary psychotic disorder, with the exception of mild anxiety disorders.
- Participants must not have a primary diagnosis of BP-I with rapid cycling (≥ 4 distinct mood episodes in one year).
- Participants must not have a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before screening, or current use as determined by urine toxicology screen or alcohol test.
- Participants must not be at risk for suicidal behavior at screening or the baseline visit as determined by the Investigator's clinical assessment and the Columbia-Suicide Severity Rating Scale (C-SSRS).
- Participants must not have cirrhosis, liver cancer, clinically significant liver disease based on the liver function test results.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Двойное слепое
- Основная цель
- Лечение
Центры проведения
США · 28 центров
- Pillar Clinical Research- Little Rock — Little Rock
- Woodland Research Northwest — Rogers
- Proscience Research Group — Culver City
- Clinical Innovations, Inc. dba CITrials — Riverside
- Collaborative Neuroscience Research, LLC — Torrance
- Local Institution - 0036 — Hialeah Gardens
- Behavioral Clinical Research — Hollywood
- LCC Medical Research Institute — Miami
- … и ещё 20 центров
Румыния · 11 центров
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Prof. Dr. Alexandru Obregia Psychiatry Hospital — Bucharest
- Local Institution - 0097 — Bucharest
- Centrul de Evaluare și Tratament a Toxicodependenței pentru Tineri Sf.Stelian — Bucharest
- … и ещё 3 центра
Индия · 8 центров
- GMERS Medical College and General Hospital — Vadodara
- Local Institution - 0082 — Belagavi
- Chethana Center for Neuropsychiatry — Kozhikode
- Dayanand Medical College and Hospital — Ludhiana
- Asha Hospital - Hyderabad — Hyderabad
- Local Institution - 0055 — Hyderabad
- Nil Ratan Sircar Medical College and Hospital — Kolkata
- Local Institution - 0096 — Kolkata
Украина · 7 центров
- Local Institution - 0088 — Dnipro
- Local Institution - 0092 — Hlevakha
- … и ещё 5 центров
Китай · 6 центров
- Local Institution - 0106 — Wuhu
- Local Institution - 0103 — Пекин
- Local Institution - 0108 — Ухань
- Local Institution - 0107 — Чанша
- Local Institution - 0105 — Jining Shi
- Local Institution - 0104 — Тяньцзинь
Израиль · 6 центров
- Shalvata Mental Health Center — Hod HaSharon
- Ness Ziona Mental Health Center — Ness Ziona
- Local Institution - 0058 — Petah Tikva
- Sheba Medical Center — Ramat Gan
- Be'er Sheva Mental Health Center — Beersheba
- Kfar Shaul Mental Health Center — Jerusalem
Хорватия · 5 центров
- Local Institution - 0009 — Zagreb
- Klinika za psihijatriju "Vrapče" — Zagreb
- Klinika za psihijatriju "Vrapče" — Zagreb
- Klinika za psihijatriju "Vrapče" — Zagreb
- Psihijatrijska bolnica "Sveti Ivan" — Zagreb
Италия · 5 центров
- Local Institution - 0001 — Milan
- Local Institution - 0056 — Pisa
- Local Institution - 0007 — Siena
- Local Institution - 0041 — Ancona
- Local Institution - 0040 — Genova
Словакия · 3 центра
- Local Institution - 0071 — Košice
- Local Institution - 0073 — Košice
- Crystal Comfort — Vranov nad Topľou
Испания · 3 центра
- Local Institution - 0069 — Barcelona
- Local Institution - 0039 — Bilbao
- Local Institution - 0044 — Barcelona
Швеция · 3 центра
- Nacka Local Hospital — Nacka
- Local Institution - 0067 — Uppsala
- Local Institution - 0070 — Gothenburg
Идентификаторы
NCT: NCT06951711 · CN012-0037 · 2024-520195-94 · U1111-1316-7466